Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma

Neuroscience Letters

Volumn 645, Issue , 2017, Pages 106-112

  Lisi, L ^a   Ciotti, G M P ^a   Braun, D ^b   Kalinin, S ^b   Curro D ^a   Dello Russo, C ^a   Coli, A ^a   Mangiola, A ^a   Anile, C ^a   Feinstein, D L ^b,c   Navarra, P ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

ARG I; CD163; Glioblastoma; iNOS; M1 polarization; M2 polarization; Microglia; Periphery; Tumor

Indexed keywords

ARGINASE 1; CD163 ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; ARGINASE; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; NOS2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CELL ACTIVATION; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; MICROGLIA; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; BRAIN TUMOR; CELL POLARITY; METABOLISM; MIDDLE AGED; PARENCHYMA; PATHOLOGY; PHYSIOLOGY; SURVIVAL ANALYSIS;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARGINASE; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELL POLARITY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MICROGLIA; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; PARENCHYMAL TISSUE; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS;

EID: 85014633979     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2017.02.076     Document Type: Article

References (42)

1. [1] Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B.A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H.S., Hodgson, J.G., James, C.D., Sarkaria, J.N., Brennan, C., Kahn, A., Spellman, P.T., Wilson, R.K., Speed, T.P., Gray, J.W., Meyerson, M., Getz, G., Perou, C.M., Hayes, D.N., Cancer Genome Atlas Research Network, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 (2010), 98–110.
2. [2] Urbańska, K., Sokołowska, J., Szmidt, M., Sysa, P., Glioblastoma multiforme – an overview. Contemp. Oncol. (Pozn) 18 (2014), 307–312.
3. [3] Tentori, L., Graziani, G., Recent approaches to improve the antitumor efficacy of temozolomide. Curr. Med. Chem. 16 (2009), 245–257.
4. [4] Giometto, B., Bozza, F., Faresin, F., Alessio, L., Mingrino, S., Tavolato, B., Immune infiltrates and cytokines in gliomas. Acta Neurochir. (Wien) 138 (1996), 50–56.
5. [5] Watters, J.J., Schartner, J.M., Badie, B., Microglia function in brain tumors. J. Neurosci. Res. 81 (2005), 447–455.
6. [6] Roggendorf, W., Strupp, S., Paulus, W., Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. 92 (1996), 288–293.
7. [7] Nishie, A., Ono, M., Shono, T., Fukushi, J., Otsubo, M., Onoue, H., Ito, Y., Inamura, T., Ikezaki, K., Fukui, M., Iwaki, T., Kuwano, M., Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. Cancer Res. 5 (1999), 1107–1113.
8. [8] Komohara, Y., Ohnishi, K., Kuratsu, J., Takeya, M., Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 216 (2008), 15–24.
9. [9] Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., Olson, O.C., Quick, M.L., Huse, J.T., Teijeiro, V., Setty, M., Leslie, C.S., Oei, Y., Pedraza, A., Zhang, J., Brennan, C.W., Sutton, J.C., Holland, E.C., Daniel, D., Joyce, J.A., CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19 (2013), 1264–1272.
10. [10] Kettenmann, H., Hanisch, U.K., Noda, M., Verhratskym, A., Physiology of microglia. Physiol. Rev. 91 (2011), 461–553.
11. [11] Saijo, K., Glass, C.K., Microglial cell origin and phenotypes in health and disease. Nat Rev. Immunol. 11 (2011), 775–787.
12. [12] Mosser, D.M., Edwards, J.P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol., 2008, 958–969.
13. [13] Franco, R., Fernández-Suárez, D., Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol. 131 (2015), 65–86.
14. [14] Hattermann, K., Sebens, S., Helm, O., Schmitt, A.D., Mentlein, R., Mehdorn, H.M., Held-Feindt, J., Chemokine expression profile of freshly isolated human glioblastoma-associated macrophages/microglia. Oncol. Rep. 32 (2014), 270–276.
15. [15] Szulzewsky, F., Pelz, A., Feng, X., Synowitz, M., Markovic, D., Langmann, T., Holtman, I.R., Wang, X., Eggen, B.J., Boddeke, H.W., Hambardzumyan, D., Wolf, S.A., Kettenmann, H., Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One, 10, 2015, e0116644.
16. [16] Dello Russo, C., Lisi, L., Tentori, L., Navarra, P., Graziani, G., Combs, C.K., Exploiting microglial functions for the treatment of glioblastoma. Curr. Cancer Drug Targets, 2016 (Aug 13. [Epub ahead of print]).
17. [17] Gabrusiewicz, K., Rodriguez, B., Wei, J., Hashimoto, Y., Healy, L.M., Maiti, S.N., Thomas, G., Zhou, S., Wang, Q., Elakkad, A., Liebelt, B.D., Yaghi, N.K., Ezhilarasan, R., Huang, N., Weinberg, J.S., Prabhu, S.S., Rao, G., Sawaya, R., Langfor, d L.A., Bruner, J.M., Fuller, G.N., Bar-Or, A., Li, W., Colen, R.R., Curran, M.A., Bhat, K.P., Antel, J.P., Cooper, L.J., Sulman, E.P., Heimberger, A.B., Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight, 1, 2016.
18. [18] Lisi, L., Stigliano, E., Lauriola, L., Navarra, P., Dello Russo, C., Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/B polarized cells. ASN Neuro 6 (2014), 171–183.
19. [19] Lisi, L., Laudati, E., Navarra, P., Dello Russo, C., The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype. J. Neuroinflammation, 11, 2014, 125.
20. [20] Mangiola, A., de Bonis, P., Maira, G., Balducci, M., Sica, G., Lama, G., Lauriola, L., Anile, C., Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer 113 (2008), 841–846.
21. [21] Sica, G., Lama, G., Anile, C., Geloso, M.C., La Torre, G., De Bonis, P., Maira, G., Lauriola, L., Jhanwar-Uniyal, M., Mangiola, A., Int. J. Oncol. 38 (2011), 41–49.
22. [22] Mangiola, A., Saulnier, N., De Bonis, P., Orteschi, D., Sica, G., Lama, G., Pettorini, B.L., Sabatino, G., Zollino, M., Lauriola, L., Colabianchi, A., Proietti, G., Kovacs, G., Maira, G., Anile, C., Gene expression profile of glioblastoma peritumoral tissue: an ex vivo study. PLoS One, 8, 2013, e57145.
23. [23] Mangiola, A., Lama, G., Giannitelli, C., De Bonis, P., Anile, C., Lauriola, L., La Torre, G., Sabatino, G., Maira, G., Jhanwar-Uniyal, M., Sica, G., Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin. Cancer Res. 13 (2007), 6970–6977 Erratum in: Clin Cancer Res. 14 (2008) 4995–4996.
24. [24] Sica, G., Lama, G., Anile, C., Geloso, M.C., La Torre, G., De Bonis, P., Maira, G., Lauriola, L., Jhanwar-Uniyal, M., Mangiola, A., Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma. Int. J. Oncol. 38 (2011), 41–49.
25. [25] D'Alessio, A., Proietti, G., Lama, G., Biamonte, F., Lauriola, L., Moscato, U., Vescovi, A., Mangiola, A., Angelucci, C., Sica, G., Analysis of angiogenesis related factors in.glioblastoma, peritumoral tissue and their derived cancer stem cells. Oncotarget 7 (2016), 78541–78556.
26. [26] Stankov, A., Belakaposka-Srpanova, V., Bitoljanu, N., Cakar, L., Cakar, Z., Rosoklija, G., Visualisation of microglia with the use of immunohistochemical double staining method for CD-68 and Iba-1 of cerebral tissue samples in cases of brain contusions. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 36 (2015), 141–145.
27. [27] Fabriek, B.O., Dijkstra, C.D., van den Berg, T.K., The macrophage scavenger receptor CD163. Immunobiology 210 (2005), 153–160.
28. [28] Fabriek, B.O., Van Haastert, E.S., Galea, I., Polfliet, M.M., Döpp, E.D., Van Den Heuvel, M.M., Van Den Berg, T.K., De Groot, C.J., Van Der Valk, P., Dijkstra, C.D., CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 51 (2005), 297–305.
29. [29] Pey, P., Pearce, R.K., Kalaitzakis, M.E., Griffin, W.S., Gentleman, S.M., Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease. Acta Neuropathol. Commun., 2, 2014, 21.
30. [30] Vogel, D.Y., Vereyken, E.J., Glim, J.E., Heijnen, P.D., Moeton, M., van der Valk, P., Amor, S., Teunissen, C.E., van Horssen, J., Dijkstra, C.D., Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J. Neuroinflammation, 10, 2013, 35.
31. [31] Rezaie, P., Male, D., Microglia in fetal and adult human brain can be distinguished from other mononuclear phagocytes through their lack of CD163 expression. Neuroembryology 2 (2003), 130–133.
32. [32] Colin, S., Chinetti-Gbaguidi, G., Staels, B., Macrophage phenotypes in atherosclerosis. Immunol. Rev. 262 (2014), 153–166.
33. [33] Lu-Emerson, C., Snuderl, M., Kirkpatrick, N.D., Goveia, J., Davidson, C., Huang, Y., Riedemann, L., Taylor, J., Ivy, P., Duda, D.G., Ancukiewicz, M., Plotkin, S.R., Chi, A.S., Gerstner, E.R., Eichler, A.F., Dietrich, J., Stemmer-Rachamimov, A.O., Batchelor, T.T., Jain, R.K., Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 15 (2013), 1079–1087.
34. [34] Prosniak, M., Harshyne, L.A., Andrews, D.W., Kenyon, L.C., Bedelbaeva, K., Apanasovich, T.V., Heber-Katz, E., Curtis, M.T., Cotzia, P., Hooper, D.C., Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin. Cancer Res. 19 (2013), 3776–3786.
35. [35] Heusinkveld, M., van der Burg, S.H., Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med., 9, 2011, 216.
36. [36] Mills, C.D., M1 and M2 macrophages: oracles of health and disease. Crit. Rev. Immunol. 32 (2012), 463–488.
37. [37] Munder, M., Eichmann, K., Morán, J.M., Centeno, F., Soler, G., Modolell, M., Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J. Immunol. 16 (1999), 3771–3777.
38. [38] Mansuy, D., Boucher, J.L., Alternative nitric oxide-producing substrates for NO synthases. Free Radic. Biol. Med. 37 (2004), 1105–1121.
39. [39] Ash, D.E., Structure and function of arginases. J. Nutr. 134:10 Suppl (2004), 2760S–2764S (discussion 2765S-2767S).
40. [40] Fazi, B., Felsani, A., Grassi, L., Moles, A., D'Andrea, D., Toschi, N., Sicari, D., De Bonis, P., Anile, C., Guerrisi, M.G., Luca, E., Farace, M.G., Maira, G., Ciafré, S.A., Mangiola, A., The transcriptome and miRNome profiling of glioblastoma tissues and peritumoral regions highlights molecular pathways shared by tumors and surrounding areas and reveals differences between short-term and long-term survivors. Oncotarget 6 (2015), 22526–22552.
41. [41] Ransohoff, R.M., A polarizing question: do M1 and M2 microglia exist?. Nat. Neurosci. 19:8 (2016), 987–991, 10.1038/nn.4338 (PubMed PMID: 27459405).
42. [42] Xue, J., Schmidt, S.V., Sander, J., Draffehn, A., Krebs, W., Quester, I., De Nardo, D., Gohel, T.D., Emde, M., Schmidleithner, L., Ganesan, H., Nino-Castro, A., Mallmann, M.R., Labzin, L., Theis, H., Kraut, M., Beyer, M., Latz, E., Freeman, T.C., Ulas, T., Schultze, J.L., Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40 (2014), 274–288.